Promoted Content

Promoted Content

All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Citryll

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Netherlands

Post An Enquiry

CPhI India 2021

Participation Not Confirmed

Update your events

Citryll Completes € 18.5 M Fundraise to Develop CIT-013, an Antibody Targeting Neutrophil Extracellular Traps

Contact the Supplier

Lead Product(s): CIT-013

Therapeutic Area: Immunology Product Name: CIT-013

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: BOM Brabant Ventures

Deal Size: $21.0 million Upfront Cash: Undisclosed

Deal Type: Financing July 02, 2020

Details:

The proceeds will be used to advance the pre-clinical and clinical development of Citryll’s CIT-013 therapeutic antibody, an inhibitor of neutrophil extracellular traps (NETs) and their formation (NETosis).